Compare · GILD vs QNCX
GILD vs QNCX
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Quince Therapeutics Inc. (QNCX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and QNCX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $163.43B, about 7538.4x QNCX ($21.7M).
- Over the past year, GILD is up 27.0% and QNCX is down 87.4% - GILD leads by 114.4 points.
- GILD has been more active in the news (12 items in the past 4 weeks vs 8 for QNCX).
- GILD has more recent analyst coverage (25 ratings vs 3 for QNCX).
- Company
- Gilead Sciences Inc.
- Quince Therapeutics Inc.
- Price
- $131.63+0.60%
- $1.32+2.71%
- Market cap
- $163.43B
- $21.7M
- 1M return
- -6.18%
- +29.02%
- 1Y return
- +26.99%
- -87.38%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2019
- News (4w)
- 12
- 8
- Recent ratings
- 25
- 3
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest GILD
- Gilead Sciences to Present at Upcoming Second Quarter 2026 Investor Conferences
- Chairman & CEO O'Day Daniel Patrick sold $1,291,608 worth of shares (10,000 units at $129.16) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 632,567 units (SEC Form 4)
- Gilead Sciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits, Other Events
- Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
- SEC Form 4 filed by Dickinson Andrew D
- SEC Form 4 filed by Mercier Johanna
- PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
- Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
Latest QNCX
- SEC Form 8-K filed by Quince Therapeutics Inc.
- SEC Form DEFA14A filed by Quince Therapeutics Inc.
- SEC Form DEF 14A filed by Quince Therapeutics Inc.
- SEC Form 8-K filed by Quince Therapeutics Inc.
- SEC Form PRE 14A filed by Quince Therapeutics Inc.
- SEC Form S-8 filed by Quince Therapeutics Inc.
- SEC Form 10-K filed by Quince Therapeutics Inc.
- Quince Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders
- SEC Form NT 10-K filed by Quince Therapeutics Inc.
- Quince Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure